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Abstract
Background: Recognizing infection is crucial in immunocompromised patients with organ dysfunction. Our
objective was to assess the diagnostic accuracy of procalcitonin (PCT) in critically ill immunocompromised patients.
Methods: This prospective, observational study included patients with suspected sepsis. Patients were classified
into one of three diagnostic groups: no infection, bacterial sepsis, and nonbacterial sepsis.
Results: We included 119 patients with a median age of 54 years (interquartile range [IQR], 42-68 years). The
general severity (SAPSII) and organ dysfunction (LOD) scores on day 1 were 45 (35-62.7) and 4 (2-6), respectively,
and overall hospital mortality was 32.8%. Causes of immunodepression were hematological disorders (64 patients,
53.8%), HIV infection (31 patients, 26%), and solid cancers (26 patients, 21.8%). Bacterial sepsis was diagnosed in 58
patients and nonbacterial infections in nine patients (7.6%); 52 patients (43.7%) had no infection. PCT
concentrations on the first ICU day were higher in the group with bacterial sepsis (4.42 [1.60-22.14] vs. 0.26 [0.09-
1.26] ng/ml in patients without bacterial infection, P < 0.0001). PCT concentrations on day 1 that were > 0.5 ng/ml
had 100% sensitivity but only 63% specificity for diagnosing bacterial sepsis. The area under the receiver operating
characteristic (ROC) curve was 0.851 (0.78-0.92). In multivariate analyses, PCT concentrations > 0.5 ng/ml on day 1
independently predicted bacterial sepsis (odds ratio, 8.6; 95% confidence interval, 2.53-29.3; P = 0.0006). PCT
concentrations were not significantly correlated with hospital mortality.
Conclusion: Despite limited specificity in critically ill immunocompromised patients, PCT concentrations may help
to rule out bacterial infection.
Keywords: bacterial infection, neutropenia, HIV infection, immune deficiency, bone marrow transplantation,
Sensitivity and Specificity.
Background
Procalcitonin (PCT), a peptide composed of 116 amino
acids, is normally produced by the C cells in the thyroid
gland. Because PCT is cleaved in the gland by a specific
protease, circulating levels are very low (< 0.1 ng/ml) in
healthy individuals. Serum PCT elevation in patients with
bacterial sepsis was first reported in 1993 [1]. Over the
last decade, PCT has gained ground as an early marker
for bacterial sepsis in emergency departments and inten-
sive care units (ICUs) [2-9]. The sensitivity and specificity
of serum PCT for diagnosing bacterial sepsis was about
80% in most studies, and PCT performed better than
CRP or other clinical or biological markers for sepsis
[4,5,9]. Moreover, in unselected ICU patients, PCT pre-
dicted mortality [4,10-12]. More recent studies showed
that PCT could be safely used to guide antibiotic use in
lower respiratory tract infections or to shorten antibiotic
treatment duration in immunocompetent patients with
sepsis [13-16].
Immunocompromised patients can produce high serum
PCT concentrations during bacterial sepsis [17-21]. How-
ever, few studies have evaluated the diagnostic perfor-
mance of PCT in immunocompromised patients, and
none have assessed the ability of PCT to diagnose bacterial
sepsis in critically ill immunocompromised patients [22].
We conducted a prospective observational study to assess
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sepsis in immunocompromised patients admitted to the
ICU.
Methods
The ethics committee of the French Society for Critical
Care approved the study (SRLF-CE 07-188). This prospec-
tive observational study was conducted in the medical
ICU of the Saint Louis teaching hospital in Paris (France)
over a 6-mo period (February-July 2007). We included all
immunocompromised patients defined as patients with
any of the following: HIV infection (all stages), neutrope-
nia (neutrophil count < 1 × 10
9/L), exposure to glucocorti-
coids (> 0.5 mg/kg for > 30 d) and/or immunosuppressive
or cytotoxic medications, solid organ transplantation, allo-
geneic or autologous stem cell transplantation, hematolo-
gical malignancy, or solid tumor. Each of the included
patients or next of kin received written information and
give oral consent. Our IRB waived the need for written
consent according to French Law.
Variables shown in Tables 1, table 2 and table 3 were
recorded at baseline and on day 3. Hospital and 28-d
survival was available for all patients. Severity of illness
was measured using the Simplified Acute Physiology
Score version II (SAPSII) [23] and the Logistic Organ
Dysfunction score (LOD) [24].
Serum PCT was assayed on ICU days 1 and 3. Blood
samples were centrifuged, decanted, aliquoted, and fro-
zen at - 80°C. PCT was assayed using a time-resolved
amplified cryptate emission (TRACE) technology assay
(Kryptor PCT; BRAHMS, Hennigsdorf, Germany); the
technicians who performed the TRACE assays were
unaware of the results of the other tests. The assays
were delayed and clinicians did not have access to the
results during the study period.
The physicians in charge of the patients prescribed the
microbiological tests and antimicrobial therapy accord-
ing to usual practice in the ICU, without interference
from the research team. The final diagnosis was estab-
lished during a meeting of all of the ICU physicians
after patient discharge. During this meeting, physicians
were unaware of the PCT level. Patients were categor-
ized as either having bacterial sepsis or not having a
bacterial infection. For descriptive results, bacterial sep-
sis was classified as microbiologically documented when
microorganisms were recovered from the infection site
or blood, and as clinically documented when objective
signs and symptoms of infection were found but cul-
tures were negative. Similarly, patients without bacterial
infections were categorized as having nonbacterial infec-
tions (fungal, parasitic, or viral) or a noninfectious
condition.
Table 1 Patient characteristics at ICU admission
Patients with
Bacterial Infection
n=5 8
Patients without
Bacterial Infection
n=6 1
Odds Ratio
(95% confidence interval)
P value
Age (years) 62.4 (45.4-70.6) 46.3 (39.1-60.5) 1.03 (1.00-1.05) 0.153
Female gender - no. (%) 23 (39.7) 27 (44.3) 0.3 (0.39-1.72) 0.61
Comorbidities
Liver disease, n (%) 2 (3.45) 4 (6.55) 1.96 (0.34-11.16) 0.44
Renal Dysfunction, n (%) 7 (12.07) 5 (8.19) 0.65 (0.19-2.18) 0.48
Diabetes mellitus, n (%) 6 (10.34) 1 (1.63) 0.14 (0.17-1.24) 0.07
COPD, n (%) 7 (12.07) 7 (11.47) 0.94 (0.31-2.88) 0.92
Heart disease, n (%) 7 (12.07) 7 (11.47) 0.94 (0.31-2.88) 0.92
Reasons for ICU admission
Acute Respiratory Failure 29(50) 21(34.42) 0.52 (2.25-1.10) 0.08
Shock 25(43.1) 4(6.55) 10.79 (3.45-33.73) < 0.001
Coma 1 (1.7) 15 (24.6) 0.54 (0.01-0.42) 0.005
Acute kidney injury 0 (0) 7 (11.47) / /
SAPSII score at admission 47.5 (38-66) 42 (30-54.5) 1.016/point (1.0-1.03) 0.05
LOD at Day 1 4 (3-6) 4 (1-6) 1.11 (0.32-1.01) 0.66
LOD at Day 3 3 (1-5) 2 (1-4) 1.1 (0.93-1.31) 0.28
Invasive ventilation on Day 1 20 (34.48) 27 (44.26) 0.66 (0.31-1.39) 0.27
Vasoactive drugs on Day 1 27 (46.55) 11 (18.03) 3.96 (1.72-9.10) 0.002
Dialysis on Day 1 7 (12.07) 6 (9.83) 1.26 (0.40-4.00) 0.69
Hospital mortality, n (%) 20 (34) 19 (31.15) 1.16 (0.54-2.50) 0.69
COPD, chronic obstructive pulmonary disease; LOD: Logistic Organ Dysfunction system;
SAPSII: Simplified Acute Physiology Score version II
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Results are reported as medians and quartiles (25th-75th
percentile) or numbers and percentages. Patient character-
istics were compared using the chi-square test or Fisher’s
exact test, as appropriate, for categorical variables, and the
nonparametric Wilcoxon test or the Kruskal-Wallis test
for continuous variables. A receiver-operating characteris-
tic (ROC) curve was plotted for the ability of PCT levels to
classify patients as having bacterial infection. A two-by-
two table was established to determine the sensitivity and
specificity for various PCT cutoff values.
To investigate associations between patient character-
istics and diagnosis of bacterial sepsis, we first per-
formed bivariate logistic regression analyses to look for
a significant influence of each variable, as measured by
the estimated odds ratio (OR) with a 95% confidence
interval (95%CI). Variables yielding P values no greater
than 0.20 in the bivariate analyses were entered into a
multiple logistic regression model. We checked to
ensure that omitting each of the selected variables
induced no significant increase in likelihood.
All of the tests were two-sided, and P values smaller
than 0.05 were considered statistically significant. Ana-
lyses were done using the SAS 9.1 software package
(SAS Institute, Cary, NC, USA).
Results
During the 6-mo study period, 320 patients were
admitted to our ICU. One hundred and nineteen
patients were included in this study; 98 (82.3%) of these
were still in the ICU on day 3. Among the 21 other
patients, 12 died and nine were discharged alive before
day 3. Patient characteristics are reported in Tables 1
and 2. The reason for immunodepression was a hemato-
logical malignancy in 64 patients (53.8%), a solid tumor
in 26 patients (21.8%), HIV infection in 31 patients
(26%, including AIDS in 19 patients [16%]), and use of
immunosuppressive agents in ten patients (8.4%). Of the
included patients, 27 had neutropenia at ICU admission
(22.7%) and eight were stem cell-transplant recipients
(6.7%; allogeneic SCT in four patients).
The physicians suspected bacterial sepsis at ICU admis-
sion in 81 (68.1%) patients (Figure 1). Antimicrobials
Table 2 Clinical and laboratory characteristics on days 1 and 3
Patient Characteristics
on days 1 and 3
Median (interquartile range)
Patients with
Bacterial Infection
n=5 8
Patients without
Bacterial Infection
n=6 1
Odds Ratio
(95% confidence interval)
P value
Clinical Characteristics
Body temperature, °C Day 1 38.5 (37.2-39.2) 37.5 (36.4-37.5) 1.37 (1.06-1.78) 0.016
Body temperature, °C Day 3 37.4 (37-38.2) 37.2 (36.6-37.6) 1.26 (0.84-1.91) 0.27
Leukocyte count, × 10
9/L Day 1 4900 (1100-12800) 8200 (4500-13500) 1.0 (1.0-1.0) 0.13
Leukocyte count, × 10
9/L Day 3 7900 (1900-15525) 7400 (3550-12942) 1.0 (1.0-1.0) 0.57
Platelet count, × 10
9/L Day 1 92500 (21000-187000) 151000 (62000-277250) 1.0 (1.0-1.0) 0.014
Platelet count, × 10
9/L Day 3 83000 (30000-217750) 115000 (53000-325000) 1.0 (1.0-1.0) 0.1
Neutrophil count, × 10
9/L Day 1 3415 (300-8690) 4370 (2375-8320) 1.0 (0.99-1.0) 0.12
Fibrinogen (g/L) Day 1 5.06 (3.32-6.29) 3.90 (2.80-5.20) 1.19 (0.99-1.42) 0.052
Fibrinogen (g/L) Day 3 4.70 (3.82-7.35) 3.80 (3.02-5.60) 1.38 (1.0-1.0) 0.09
Lactate (mmol/L) Day 1 2.15 (1.3-4.5) 1.9 (1.37-2.83) 1.17 (0.99-1.38) 0.06
Lactate (mmol/L) Day 3 1.60 (1.23-2.25) 1.30 (0.97-1.78) 1.19 (0.69-2.05) 0.53
Procalcitonin (ng/ml) Day 1 4.42 (1.57-22.14) 0.26 (0.09-1.26) 1.05 (1.01-1.09) 0.005
Procalcitonin (ng/ml) Day 3 3.19 (1.17-16.13) 0.45 (0.10-1.69) 1.05 (1.01-1.09) 0.03
Table 3 Microbiogical finding in the 24 patients with
microbiogically documented bacterial infection and the 9
patients with non-bacterial infection
n = 34 (%)
Bacterial infection 24 (70.6)
Positive blood culture 20
Enterobacteria 13(38.2)
Pseudomonas Aeruginosa 5(14.7)
Stenotrophomonas maltophilia 1(2.9)
Listéria Monocytogenes 1(2.9)
Clostridium Spp 1(2.9)
Streptococcus 2(5.9)
Coagulase negative Staphylococcus 1(2.9)
Non bacterial infection 9 (29.4%)
Fungal infection 5(14.7)
Candida Albicans 1(2.9)
Aspergillus Fumigatus 1(2.9)
Pneumocystis Jirovecii 2(5.9)
Fusarium 1(2.9)
Parasitic infection 3(8.8)
Toxoplasmosis 3(8.8)
Viral infection 1(2..9)
Herpes simplex 1 (2.9)
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and they were administered on the first ICU day to 82
(69%) patients.
The final diagnosis was clinically documented bacter-
ial sepsis in 34 (28.6%) patients and microbiologically
documented bacterial sepsis in 24 (20.2%) patients;
thus, 58 (48.7%) patients had bacterial infections. Of
the remaining patients, 61 patients had no bacterial
infection, including nine patients with nonbacterial
infections (7.6%) and noninfectious conditions in 52
(43.7%) patients. Of the patients with microbiologically
documented bacterial infections, 20 (83.3%) had posi-
tive blood cultures (Table 3). Diagnoses in patients
with noninfectious conditions were mainly malignant
organ infiltration in 15 patients (28.9% of patients with
noninfectious conditions), noninfectious neurological
involvement in 11 patients (21.1% of patients with
noninfectious conditions), cardiovascular events
(including pulmonary embolism and cardiogenic pul-
monary edema) in nine patients (17.3% of patients
with noninfectious conditions), metabolic complica-
tions in nine patients (acute kidney injury or tumor
lysis syndrome; 17.3% of patients with noninfectious
conditions), and other noninfectious life threatening
events in eight patients (15.4% of patients with nonin-
fectious conditions).
Serum PCT concentrations on days 1 and 3 were sig-
nificantly higher in patients with bacterial infections
compared to all other patients (P < 0.0001; Figure 2,
panel A). Patients with septic shock had higher serum
PCT concentrations than patients who had severe sepsis
without shock (15.18 ng/ml [4.17-48.81] vs 2.00 ng/ml
[0.89-7.65]; P < 0.0001).
ROC curves are reported in Figure 3. The area under
the curve (AUC) was 0.851 (95%CI 0.782-0.919). A cut-
off value of 0.5 ng/ml was associated with 100% sensitiv-
ity but only 63% specificity. The performance of PCT at
various cut-offs is reported in Table 4. In a multivariate
analysis where bacterial infection was the outcome vari-
able of interest, PCT concentrations of > 0.5 ng/ml
independently predicted bacterial sepsis (Table 5).
All of the 58 patients with clinically or microbiologi-
cally documented bacterial infections had PCT values
above 0.5 ng/ml and all received antimicrobial agents.
Among the 24 patients admitted with suspected bacterial
infections but in whom bacterial infection was seconda-
rily ruled out, 15 (62%) had PCT values < 0.5 ng/ml and
all but one received antimicrobial agents. Including PCT
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immunocompromized 
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Figure 1 Patient flow chart.
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tivity threshold of 0.5 ng/ml would have avoided antimi-
crobial therapy in 15 patients on day 1. Of the nine
patients with nonbacterial infections, one patient had
viral infection (PCT 4.3), five patients had fungal infec-
tions (median [IQR] PCT = 0.37, range 0.17-32.3) and
three had parasitic infections (median PCT = 0.37, range
0.11-4.6). Multivariate analysis identifying independent
predictors for bacterial infection are reported in table 5.
ICU and hospital mortality rates were 20.2% (24
deaths) and 32.8% (39 deaths), respectively. PCT con-
centrations on ICU days 1 and 3 were not significantly
different in survivors and decedents (Figure 2, panel B).
Independent predictors of hospital mortality (Table 6)
were age (OR 1.03/y, 95%CI 1.001-1.06; P = 0.04) and
invasive mechanical ventilation (OR 3.43, 95%CI 1.27-
9.26; P = 0.01). Disseminated intravascular coagulation
(DIC) at ICU admission was found to be protective
against hospital mortality in the studied population (OR
0.96, 95%CI 0.94-0.99; P = 0.01).
Discussion
In this study, we evaluated the performance of PCT
concentration as a marker for bacterial infection in
immunocompromised patients admitted to the ICU.
Higher PCT levels were not associated with hospital
mortality. In addition, PCT concentrations were of lim-
ited value in diagnosing bacterial infection. Nevertheless,
in our study population, PCT concentrations accurately
ruled out a diagnosis of bacterial infection at a threshold
of 0.5 ng/ml.
The absence of an association between PCT and mor-
tality is in conflict with previously published studies in
nonimmunocompromised patients, in which PCT levels
at admission and daily thereafter correlated closely with
hospital mortality [4,25,26]. This discrepancy can prob-
ably be ascribed to the impact of the underlying immu-
nosuppression and organ dysfunctions on mortality.
Regarding diagnostic performance, PCT levels on day 1
were significantly associated with bacterial infection.
The area under the ROC curve was 0.851 (95% CI
a. b.
c.
Figure 2 Procalcitonin levels (ng/ml) in patients with bacterial infection and in the other patients on Day 1 and Day 3 (panel A) and
in survivors and nonsurvivors (panel B).
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tivity. Similarly, in a study of immunocompromised
patients with suspected pulmonary infection, serum
PCT significantly predicted bacterial infection [21].
Moreover, the cutoff values found in our study are very
close to those reported in nonimmunocompromised
patients.
In nonimmunocompromised patients, serum PCT
levels at admission and daily thereafter have been used
to guide antibiotic prescriptions. PCT guidance substan-
tially reduced antibiotic use in patients with lower
respiratory tract infections and community-acquired
pneumonia [13,14,26] and in patients admitted to the
ICU with bacterial sepsis [16]. Our results suggest that
PCT guidance might also be helpful in immunocompro-
mised ICU patients.
Our study has several limitations. First, our population
of immunocompromised patients was heterogeneous.
While this diversity reflects everyday reality in ICUs, it
may have led us to miss findings specific to particular
subgroups. Moreover, 22% of patients had neutropenia
upon ICU admission, a condition that requires special
care when evaluating PCT. Second, the serum PCT level
was measured on days 1 and 3. In most studies, PCT was
measured at admission and a few hours later, allowing
for a better assessment of the risk of bacterial infection.
Our findings and earlier data support serial PCT mea-
surement in patients who are not on antimicrobials. In
addition, we included both microbiologically and clini-
cally documented bacterial infection. Indeed, in the stu-
died population, most of the included patients received
antibiotics before ICU admission. This characteristic of
the studied population may have limited the proportion
of patients in whom microbiological documentation was
possible. This choice may have induced a bias in evaluat-
ing the diagnostic performance of PCT. Similarly, the
microbiological investigations were not standardized in
the studied population, which also limits how our results
can be interpreted. However, final classification of the
patients was performed by physicians who were unaware
of the PCT concentration. This may have limited the
impact of the previously mentioned biases. Finally, bac-
terial infection is not the only factor that can lead to PCT
elevation. Several solid malignancies, such as small-cell
carcinoma of the lung and thyroid cancers, can sponta-
neously release PCT in the absence of bacterial infection.
However, none of our patients had these types of tumors.
Conclusion
PCT may help to rule out bacterial infection in immu-
nocompromised patients admitted to the ICU. Although
the performance of PCT concentrations as a diagnostic
hZKĐƵƌǀĞ͗Ϭ͘ϴϱϭ
Figure 3 ROC curve analysis of the performance of
procalcitonin for diagnosing bacterial infection on the first day
in the ICU.
Table 4 Performance of procalcitonin for detecting patients with bacterial infection at various cutoff values (± 95%CI)
PCT (ng/ml) PCT > 0.5 PCT > 1.35 PCT > 2 PCT > 5
Bacterial infection prevalence = 48.7%
Sensitivity 1.00 ± 0.00 0.81 ± 0.11 0.67 ± 0.12 0.50 ± 0.13
Specificity 0.63 ± 0.12 0.77 ± 0.11 0.82 ± 0.08 0.90 ± 0.08
Positive predictive value 0.72 ± 0.06 0.77 ± 0.10 0.78 ± 0.08 0.83 ± 0.15
Negative predictive value 1.00 ± 0.00 0.81 ± 0.11 0.72 ± 0.08 0.65 ± 0.08
Positive likelihood ratio 2.70 3.52 3.72 5.00
Negative likelihood ratio 0.00 0.25 0.40 0.56
Younden’s index 0.63 0.58 0.49 0.40
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be investigated further in a larger study, and that an
interventional study of antibiotic prescriptions guided by
repeated PCT measurements in non-neutropenic immu-
nocompromised patients is required.
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